Glenmark Pharmaceuticals Overview: Pipeline, Partnerships & Future Plans
Glenmark Pharmaceuticals Ltd. is a leading global pharmaceutical company headquartered in Mumbai, India. Founded in 1977 by Gracias Saldanha, the company has evolved from a generics-focused manufacturer into a research-driven, innovation-led enterprise. With a strong presence in over 80 countries, Glenmark operates across key therapeutic areas including dermatology, respiratory, oncology, cardiology, and diabetes.
Company Overview-
- Founded: November 18, 1977
- Headquarters: Mumbai, India
- Founder: Gracias Saldanha
- Managing Director & Chairman: Glenn Saldanha
- Employees: ~15,500 (as of 2023)
- Business Focus: Generics, Branded Formulations, Oncology, Respiratory, Dermatology, Cardio, Anti-diabetics
- Global Reach: Operations in over 80 countries
🧬 Key Business Segments of Glenmark Pharmaceuticals
1. Branded Formulations
- Description: Prescription medications marketed under Glenmark’s brand, mainly in emerging markets like India, Latin America, Asia, CIS, and Africa.
- Therapeutic Focus:
- Dermatology
- Respiratory (e.g., asthma, COPD)
- Cardiology
- Diabetes
- Oncology (emerging portfolio)
- Market Position:
- Among the Top 15 pharma companies in India
- Leading in dermatology and respiratory care segments in India and Russia
- Key Brands: Momate, Ascoril, Candid, Telma, Zita, Fabulas
2. Generics Business
- Description: Generic (off-patent) medicines supplied to highly regulated markets such as the US, Europe, and Japan.
- Strengths:
- Over 170 ANDA approvals in the US
- Large-scale manufacturing infrastructure in India and the US
- Diverse formulations: oral solids, injectables, topicals, and inhalation therapies
- Products: Generic versions of cardiovascular drugs, diabetes treatments, dermatological and anti-infective products
3. Active Pharmaceutical Ingredients (API)
- Description: Manufacturing and export of bulk drug ingredients used by other pharmaceutical companies to produce final formulations.
- Capabilities:
- Strong in complex APIs and backward integration
- EU-GMP and US FDA-compliant facilities
- Export Markets: North America, Europe, Latin America, and Japan
4. Specialty & Innovation – Biologics & Oncology
- Key Driver: R&D-driven business through its Swiss-based innovation arm Ichnos Glenmark Innovation (IGI)
- Therapeutic Focus: Oncology, Immunology, and Pain
- Strategic Milestone:
- ISB-2001: Trispecific T-cell engager licensed to AbbVie in 2025
- ISB-1442: CD38 x CD47 bispecific for blood cancers (in Phase 1)
- GRC-54276: HPK1 inhibitor for solid tumors (in Phase 1)
- Recent India Launches:
- Tevimbra (tislelizumab) – immuno-oncology drug
- Brukinsa (zanubrutinib) – BTK inhibitor
5. Consumer Healthcare (Over-the-Counter Products)
- Scope: Non-prescription health and wellness products
- Product Examples: Candid Dusting Powder, Scalpe shampoo, VWash (feminine hygiene)
- Market Position: Growing presence in India’s OTC segment
🧩 Business Model Overview
| Segment | Revenue Contributor | Strategic Focus Area |
|---|---|---|
| Branded Formulations | High | Growth in emerging markets |
| Generics | Moderate | Volume-driven growth in US & EU |
| APIs | Low to moderate | Integrated supply chain, supports formulations |
| Innovation (IGI) | Long-term high | Licensing, biologics, oncology partnerships |
| Consumer Healthcare | Emerging | Brand building and direct-to-consumer (D2C) |
📊 Strategic Priorities (2025 & Beyond)
- Oncology Innovation: Strengthen pipeline and monetize via licensing (e.g., AbbVie deal)
- Branded Growth: Expand India and emerging market portfolios
- Generics & Compliance: Maintain regulatory discipline in US/Europe
- Cost Optimization: Leverage Indian manufacturing to sustain margins
- Consumer Healthcare: Expand OTC presence through brand innovation
🏢 Glenmark Pharmaceuticals – Company Information
🧱 Manufacturing Plants
Glenmark operates 14 manufacturing facilities worldwide, designed to meet global regulatory standards including US FDA, EU EMA, and WHO-GMP.
🌍 India
- Goa (Verna) – US FDA & EU approved; solid oral formulations
- Baddi (Himachal Pradesh) – Tablets, capsules, ointments; WHO GMP certified
- Indore (MP) – Semi-solids, topicals, oral solids
- Aurangabad (Maharashtra) – API manufacturing
- Ankleshwar (Gujarat) – API & intermediate manufacturing
- Dahej (Gujarat) – US FDA approved; high-volume APIs
- Sikkim – Domestic formulations
🌎 Global Facilities
- Monroe, North Carolina (USA) – Oral solids for US market; inspected by US FDA (2025: 5 minor observations)
- Buenos Aires (Argentina) – Local market focus
- Vysoké Mýto (Czech Republic) – Semi-solids and liquids for Europe
🧪 R&D Centers
- Navi Mumbai (India) – Formulations, APIs, generics
- Lausanne (Switzerland) – Ichnos Glenmark Innovation (IGI) – Biologics, immuno-oncology
- Mahape (India) – Advanced analytics, early-stage drug discovery
- Paramus, New Jersey (USA) – NDAs, 505(b)(2) filings for regulated markets
🧑💼 Corporate Hierarchy & Leadership
| Position | Name | Role |
|---|---|---|
| Chairman & MD | Glenn Saldanha | Strategic vision, innovation, global ops |
| Chief Financial Officer | Piyush Sharma | Finance, investor relations |
| President – India Form. | Alok Malik | Domestic branded business |
| President – API Business | Saikat Ghosh | Global API production & marketing |
| Head – US Generics | Robert Matsuk | US commercial operations |
| CEO – IGI (Ichnos) | Cyril Konto | Biologics pipeline & innovation R&D |
Glenmark follows a decentralized matrix structure, empowering regional business heads under a global innovation and compliance framework.
⚖️ Regulatory Approvals & Certifications
- US FDA – Multiple facilities regularly inspected
- EMA (Europe) – Facilities in India and Czech Republic certified
- ANMAT (Argentina)
- PMDA (Japan)
- TGA (Australia)
- WHO-GMP
- MHRA (UK)
Glenmark has filed over 170 ANDAs in the US and holds multiple marketing authorizations across Latin America, Africa, and Europe.
🌐 Global Market Presence
| Region | Presence Type |
|---|---|
| India | Major branded market; Top 15 pharma player |
| USA | Major generics market; oral & injectable |
| Europe | API + semi-solid formulations via Vysoké |
| Latin America | Argentina facility, branded generics |
| Russia/CIS | Strong respiratory & dermatology presence |
| Middle East/Africa | Growing branded formulations business |
| Asia (Emerging) | Focus on biosimilar and oncology entry |
📈 Research Capabilities & Pipeline Highlights
- ISB-2001 – Trispecific antibody for Multiple Myeloma (Phase 1)
- ISB-1442 – CD38 x CD47 bispecific (Phase 1)
- GRC-54276 – HPK1 inhibitor (solid tumors; Phase 1)
- Licensed Molecules: Tevimbra (BeiGene), Brukinsa
📦 Product Categories
| Category | Description |
|---|---|
| Branded Formulations | India, Russia, Latin America |
| Generics | US, Europe, Japan |
| APIs | Supplied globally, vertical integration |
| Consumer Healthcare | Candid, Scalpe, VWash OTC range |
| Biologics & Oncology | Focus of R&D and innovation partnerships |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. is a research-led global pharmaceutical company headquartered in Mumbai, India. Founded in 1977 by Gracias Saldanha, Glenmark has transformed over the decades from a generics-focused enterprise into an innovation-driven organization with a strong presence in both emerging and developed markets.
With operations in more than 80 countries, Glenmark offers a diverse portfolio of branded formulations, generic medicines, active pharmaceutical ingredients (APIs), and increasingly, innovative biologics and oncology therapies. The company’s therapeutic expertise spans key segments such as dermatology, respiratory, cardiology, diabetes, oncology, and infectious diseases.
At the heart of its innovation strategy lies Ichnos Glenmark Innovation (IGI), a Switzerland-based R&D subsidiary focusing on next-generation biologics in oncology and immunology. Glenmark’s groundbreaking trispecific antibody, ISB-2001, has received Fast Track designation from the US FDA and was licensed to AbbVie in a $700 million upfront deal, showcasing the company’s global R&D capabilities.
Glenmark’s manufacturing and research infrastructure spans across India, the United States, Argentina, and Europe, with approvals from leading regulatory agencies like US FDA, EMA, and WHO-GMP. Its strong domestic footprint in India makes it a top player in branded generics, while its US and European operations continue to deliver value through high-volume generic formulations.
As of 2025, Glenmark employs more than 15,500 professionals worldwide and continues to invest heavily in R&D, aiming to strike a strategic balance between high-growth innovation and stable generics revenue. With an expanding oncology pipeline, high-impact global partnerships, and a renewed focus on compliance and sustainability, Glenmark is well-positioned to lead in the evolving global pharma landscape.
Contact Information for Glenmark Pharmaceuticals:
📍 Registered & Corporate Offices
Registered Office
Glenmark Pharmaceuticals Ltd.
B/2, Mahalaxmi Chambers
22, Bhulabhai Desai Road, Mumbai – 400 026, India (Glenmark Pharma, Scalpe Pro)
Corporate Office
Glenmark House, B. D. Sawant Marg
Chakala, Off Western Express Highway
Andheri (East), Mumbai – 400 099, India
📞 +91‑22‑4018 9999 📠 Fax: +91‑22‑4018 9986 (Glenmark Pharma)
📞 Phone & Fax Directory
- Primary Tel (Mumbai offices): +91‑22‑4018 9999
- Toll-Free Customer Support (India): 1800‑266‑6255 (9 AM–6 PM IST, Mon–Fri) (glenmarkonline.com)
- Fax: +91‑22‑4018 9986 (Glenmark Pharma)
✉️ Email Contacts
- Media Relations: CorpComm@glenmarkpharma.com
- Investor Relations / Compliance Officer: ComplianceOfficer@glenmarkpharma.com
- General Customer Support: globalcustomerservice@glenmarkpharma.com
- Grievance Officer: grievance.officer@glenmarkpharma.com
- Business Development & Partnerships: businessdevelopment.web@glenmarkpharma.com (Glenmark Pharma, India Customer Care)
🏢 Registrar & Share Transfer Agent
KFIN Technologies Limited
Selenium Building, Tower‑B, Plot 31 & 32, Financial District
Nanakramguda, Serilingampally, Hyderabad – 500 032, Telangana, India
📞 Toll-Free: 1800‑309‑4001 WhatsApp: +91‑910 009 4099
📧 einward.ris@kfintech.com (Glenmark Pharma)
🧭 Summary of Contact Options
| Department | Contact Details |
|---|---|
| Corporate Communication | +91‑22‑4018 9999 / CorpComm@glenmarkpharma.com |
| Investors | +91‑22‑4018 9999 / ComplianceOfficer@glenmarkpharma.com |
| Customer Support | 1800‑266‑6255 / globalcustomerservice@glenmarkpharma.com |
| Business Development | businessdevelopment.web@glenmarkpharma.com |
| Registrar (KFINTech) | 1800‑309‑4001 / einward.ris@kfintech.com |
